title: [Liver transplantation in hepatitis B viral infection].
abstract: Hepatitis B infection (HBV) causes liver cirrhosis and hepatocellular carcinoma that are indications for orthotopic liver transplantation (OLT). The outcome of OLT depends on the prevention of HBV reinfection and disease relapses. Out of 692 liver transplantations performed at Merkur University Hospital, 30 were done for HBV infection. These patients were treated with HBIG post OLT and lamivudine, entecavir, adefovir, tenofovir prior and post OLT. All patients became HBsAg and HBV DNA negative but four of them became HbsAg positive one year post OLT. The patients survived for 2 months to 7 years post OLT. With the introduction of HBIG immunoprophylaxis and new efficient antiviral treatment, the risk of relapse is only < 10%, and survival is the same as in other indications for OLT. Because of the high cost and long-term treatment, efforts have been made to prevent recurrent HBV disease by using the schedules according to pre- and post-transplant HBV viremia and introducing the new potent antiviral analogue nucleos(t)ides.
authors.forename: Tajana Filipec
authors.initials: TF
authors.lastname: Kanizaj
authors.forename: Vesna
authors.initials: V
authors.lastname: Colić-Cvrlje
authors.forename: Anna
authors.initials: A
authors.lastname: Mrzljak
authors.forename: Rajko
authors.initials: R
authors.lastname: Ostojić
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000628:therapy*; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006801:Humans; D016031:Liver Transplantation; D008875:Middle Aged; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens